SARS-CoV-2 cell entry and targeted antiviral development

  • Acta Pharm Sin B. 2021 Dec;11(12):3879-3888. doi: 10.1016/j.apsb.2021.05.007.
Zinuo Chen  1 ,  Ruikun Du  1  2  3 ,  Jazmin M Galvan Achi  4 ,  Lijun Rong  4 ,  Qinghua Cui  1  2  3
Affiliations
  • 1. College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
  • 2. Qingdao Academy of Chinese Medicinal Sciences, Shandong University of Traditional Chinese Medicine, Qingdao 266122, China.
  • 3. Experimental Center, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
  • 4. Department of Microbiology and Immunology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA.
PMID: 34002130 DOI: 10.1016/j.apsb.2021.05.007
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the pandemic coronavirus disease 2019 (COVID-19), which threatens human health and public safety. In the urgent campaign to develop anti-SARS-CoV-2 therapies, the initial entry step is one of the most appealing targets. In this review, we summarize the current understanding of SARS-CoV-2 cell entry, and the development of targeted Antiviral strategies. Moreover, we speculate upon future directions toward next-generation of SARS-CoV-2 entry inhibitors during the upcoming post-pandemic era.

Keywords
Antiviral development; Cell entry; Post-pandemic; SARS-CoV-2; Spike protein.
Products